Lidoflazine
Lidoflazine is a piperazine calcium channel blocker. It is a coronary vasodilator with some antiarrhythmic action.[1] Lidoflazine was discovered at Janssen Pharmaceutica in 1964.
 | |
| Clinical data | |
|---|---|
| AHFS/Drugs.com | International Drug Names |
| ATC code | |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| KEGG | |
| CompTox Dashboard (EPA) | |
| ECHA InfoCard | 100.020.285  |
| Chemical and physical data | |
| Formula | C30H35F2N3O |
| Molar mass | 491.627 g·mol−1 |
| 3D model (JSmol) | |
| Melting point | 159 to 161 °C (318 to 322 °F) |
| Solubility in water | Almost insoluble in water(<0.01%); Very soluble in chloroform(>50%); mg/mL (20 °C) |
| |
| |
  (what is this?) (verify) | |
Physical properties
Solubility at room temperature
Extracted from[1]
| Solvent | 0.01
N |
0.1
N | ||
| % | pH | % | pH | |
| Hydrochloric Acid | 0.4 | 3.0 | 0.7 | 1.9 |
| Tartaric Acid | 0.3 | 3.1 | 1.0 | 2.5 |
| Citric Acid | 0.3 | 3.1 | 0.5 | 2.5 |
| Lactic Acid | 0.2 | 3.4 | 0.7 | 2.9 |
| Acetic Acid | 0.1 | 3.5 | 0.4 | 3.8 |
References
- Schaper WK, Xhoneux R, Jageneau AH, Janssen PA (May 1966). "The cardiovascular pharmacology of lidoflazine, a long-acting coronary vasodilator". The Journal of Pharmacology and Experimental Therapeutics. 152 (2): 265–74. PMID 5944369.
Further reading
- Schaper WK, Xhonneux R, Jageneau AH (November 1965). "Stimulation of the coronary collateral circulation by lidoflazine (R 7904)". Naunyn-Schmiedebergs Archiv für Experimentelle Pathologie und Pharmakologie. 252 (1): 1–8. doi:10.1007/bf00246424 (inactive 2021-01-11). PMID 4222721.CS1 maint: DOI inactive as of January 2021 (link)
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.